SOURCE: Nutranomics Inc.

Nutranomics Inc.

January 07, 2016 09:30 ET

Nutranomics, Inc. Announces the Appointment of Company Founder, Dr. Tracy Gibbs, as CEO

SALT LAKE CITY, UT--(Marketwired - Jan 7, 2016) - Nutranomics, Inc (OTC PINK: NNRX) announces the re-instatement of company founder Dr. Tracy Gibbs as the company's CEO. Dr. Gibbs has previously served as CEO from Nutranomics' inception in 1995 until 2014. He has been the company's chief scientist and corporate visionary.

With the company's recent shift in business plan, where focus is more acutely placed on new product development and the marketing of its new line of OneCare supplements, Dr. Gibbs' understanding of the Nutranomics core science becomes paramount as the company begins a new marketing and sales campaign in both the U.S. and Asia. 

"I want to thank the previous management team for helping to achieve many of our short-term operating objectives," said Dr. Gibbs. "It feels like the timing is right to step back into the product development and marketing, where my understanding of our product line and of our traditional consumer becomes very valuable." The company intends to place additional focus on new business development and top line revenue growth in the coming twelve months.

Dr. Gibbs founded Nutranomics based upon his scientific background in vitamins and supplemental healthcare products and the desire to create something better for those concerned with living a healthy lifestyle. He has formulated multiple nutritional supplements as an OEM for various large vitamin retailers and private label distributors. The company has re-committed its focus to the development of new, cutting edge nutritional products that it will sell both via brick and mortar retailers and through its website The company's formulas are 'best-in-class', providing healthier alternatives to traditional name brand dieting and supplement products. One of Dr. Gibbs first orders of business will be to provide a comprehensive shareholder update within the coming weeks referencing sales objectives and forecasting for 2016. 

Contact Information

  • For further information, contact the company directly at 800-745-0393 or the view investor relations tab at